Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Paul-Peter Tak |
Contact Details
Address: 117 Kendrick Street, Suite 450 Needham, Massachusetts 02494 United States | |
| Phone | 617 916 5445 |
| Website | candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical and Development Officer |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Charles Schoch | Senior Vice President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary |
| Ileen B. Winick | Chief People Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Dr. William Nichols Garrett M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 18, 2026 | SCHEDULE 13D/A | Filing |
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 424B5 | Filing |
| Feb 19, 2026 | 424B5 | Filing |
| Feb 19, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G | Filing |